Hi, my name is Hanje Cho. I'm an associate professor in the Multiple Myeloma Center of Excellence at the Tisch Cancer Institute at Mount Sinai Icahn School of Medicine in New York City. I'm also the chief medical officer for the Multiple Myeloma Research Foundation. TASCH 2022 has featured some incredibly exciting developments in the world of immunotherapy for multiple myeloma. We already had the approvals for CAR T cells against BCMA, and we're hearing about new CAR T cell technologies, including allogeneic CAR T cells and multi-targeted CAR T cells. And we've recently had the approval of Teclistumab, the first BCMA-directed T cell engaging agent, and we've heard a lot more data here about T cell engagers against other targets and in combinations with standard of care therapies. So this is an incredible development, accelerating the progress toward curative treatment. But we've also now recognized that there are significant risks with these powerful immunotherapy agents, in particular, the long-term risks of serious infections. So there's an urgent need for continued research into how we can best use these powerful immunotherapeutic agents in pursuit of curative therapy for multiple myeloma. And we are now starting to hear about innovative clinical trials using different dosing schedules and different dosing schemes in order to accomplish this. So I think we've made a lot of progress, and it's been a great meeting to hear about this. But we also have to recognize that the job is not done, and we have a long way to go.
HealthTree • December 20, 2022